You are here: Industry Insights > HbA1c

News List

Centaur Pharma to start post-marketing surveillance study of diabetic drug by end of January 2021 expresspharma
January 14, 2021
The company, with permission to conduct the PMS study in 200 to 500 patients with diabetic foot ulcers, plans to enrol them from three to four government sites as well as other hospitals in all cities that have diabetic foot clinics or OPD.
HbA1c Minimally Adds to CVD Risk Prediction in Prediabetes drugs
December 27, 2019
For individuals with prediabetes, hemoglobin A1c (HbA1c) minimally adds to cardiovascular disease (CVD) risk prediction, according to a study published online December in Diabetes Care.
HbA1c, BMI Linked to Stillbirth Risk in Women With Diabetes drugs
August 12, 2019
Higher maternal hemoglobin A1c (HbA1c) levels are associated with increased risk for stillbirth among women with type 1 diabetes...
Oral Semaglutide Reduces HbA1c, Weight in Patients With T2DM drugs
August 01, 2019
Compared with placebo, oral semaglutide monotherapy is associated with superior and clinically relevant improvements in glycated hemoglobin (HbA1c) ...
NICE recommendation for Steglatro in type II diabetes pharmatimes
March 28, 2019
The National Institute of Care and Health Excellence (NICE) has recommended MSD’s Steglatro (ertugliflozin) for use within the NHS, for the treatment of adults with type II diabetes.
Novo’s oral semaglutide bests MSD’s Januvia on HbA1c reduction pharmatimes
July 05, 2018
Novo Nordisk has presented data from a Phase IIIa study showing that an oral formulation of its GLP-1 analogue semaglutide was better at reducing blood sugar than MSD’s DPP-4 inhibitor Januvia in patients with type II diabetes.